All Search Results
News Releases
Sep 29, 2026, 03:45 ET 2026 IMS Oral Presentation: Innovent Announces Updated Phase 1 Clinical Data of Trispecific Antibody IBI3003 (GPRC5D/BCMA/CD3) in Patients with Relapsed or Refractory Multiple Myeloma
IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA, and CD3, in patients with relapsed or refractory multiple myeloma (R/R MM) in an oral presentation at the 23rd International Myeloma Society (IMS) Annual Meeting 2026. Based on the results of the Phase 1 dose optimization study, the recommended Phase
More news about: Innovent Biologics
Sep 26, 2026, 23:16 ET 2026 IMS | IASO Bio Presented FUCASO China Real-World Data
autoleucel injection, Eque-cel) — for the treatment of relapsed/refractory plasma cell neoplasms were formally presented at the 2026 International Myeloma Society (IMS) Annual Meeting, and reported by Professor Jin Lu of Peking University People's Hospital as an oral presentation at the meeting (Abstract
More news about: IASO Bio
Sep 26, 2026, 23:03 ET 2026 IMS | IASO Bio Presented First-in-Human Data of BCMA-Targeted In Vivo CAR-T Cell Therapy IASO206
for IASO206, its internally developed BCMA-targeted in vivo CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (R/R MM) at the 2026 International Myeloma Society (IMS) Annual Meeting. IASO206 is designed to generate functional BCMA-directed CAR-T cells directly in patients
More news about: IASO Bio
Sep 25, 2026, 11:32 ET 2026 IMS | IASO Bio Presents First-in-Human Phase 1 Data of RD140, a Fully Human BCMA/GPRC5D Dual-Targeted FasT CAR-T
based on the FasT CAR-T rapid manufacturing platform — at the 2026 International Myeloma Society (IMS) Annual Meeting. The study is an investigator-initiated trial (IIT) in patients with relapsed/refractory multiple myeloma (R/R MM) and plasma cell leukemia (PCL), designed to evaluate the safety, tolerability,
More news about: IASO Bio
Sep 25, 2026, 10:54 ET 2026 IMS | Updated FUMANBA-1 Analysis of IASO Bio's FUCASO Reveals That In Vivo Durable Persistence of CAR-T cells Is Associated with Sustained MRD Negativity and Delayed Disease Progression
product, FUCASO (equecabtagene autoleucel injection, Eque-cel) — were presented as a poster at the 2026 International Myeloma Society (IMS) Annual Meeting[1] (Abstract No.: PA-469). The results showed that durable persistence of FUCASO
More news about: IASO Bio
Organizations
Resources
News Trends
AI in Medtech, Employee Wellbeing: The Latest Health News Trends
FDA approved TALVEY™ (talquetamab-tgvs), an antibody used in the treatment of adult patients with relapsed or refractory multiple myeloma, a difficult-to-treat blood cancer. At the end of August, CVS Health